Japan Hepatitis C Settlement Set To Cover Only 10 Percent
This article was originally published in PharmAsia News
The Japanese government settlement with hepatitis C patients, set for Osaka High Court review Feb. 7, is likely to cover only 10 percent of those infected, according to a plaintiff lawyer. The lawyer said the others have not been able to prove the source of their infection and probably will not be covered. The cases were linked to blood products provided by Mitsubishi Tanabe Pharma, but many patient records were destroyed before a connection could be determined. Mitsubishi Tanabe's Green Cross unit, a defendant in one suit, is to share in the settlement payout. (Click here for more
You may also be interested in...
Former Japan Pharmaceutical and Food Bureau Chief, Akira Miyajima, resigned on Jan. 17 as CEO of the Pharmaceutics and Medical Devices Agency. His resignation is believed to be an effort to take responsibility for brushing aside a list of hepatitis C cases caused by contaminated blood products, and failing to notify patients about the information (PharmAsia News, Jan. 17, 2008). In August 2002, the Ministry of Health, Labor and Welfare received a list from pharmaceutical companies of the cases of 418 hepatitis C patients; the information included duration of drug administration and each patient's symptoms. However, the list was not delivered to the patients themselves. It is believed that the failure to transmit this information led to a worsening in the cases. (click here for more - may require subscription
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.